Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome — ViDMe

Cutaneous Malignant Melanoma Clinical Trial

Official title:
Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome

Status Completed

Clinical Trial Summary

To assess whether vitamin D supplementation after surgery of a first cutaneous malignant melanoma protects against relapse of the disease.

Clinical Trial Description

To assess whether vitamin D supplementation, in the follow up period after diagnosis and surgery of a first cutaneous malignant melanoma, has a protective effect on relapse of cutaneous malignant melanoma and whether this protective effect correlates with vitamin D levels in serum and vitamin D receptor (VDR) immunoreactivity in the primary tumor. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01748448
Study type	Interventional
Source	Universitaire Ziekenhuizen KU Leuven
Contact
Status	Completed
Phase	Phase 3
Start date	December 2012
Completion date	July 2022

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT06388252` - Electrochemotherapy Induces Changes in the Tumor Microenvironment of Cutaneous and Subcutaneous Metastases in Patients With Cutaneous Melanoma	N/A
Recruiting	`NCT04620603` - Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer	Phase 1/Phase 2
Completed	`NCT02308553` - Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma	Phase 1/Phase 2
Completed	`NCT01482260` - Comparative Microarray Analysis in Primary Cutaneous Malignant Melanoma	N/A